Erythropoietin monotherapy for neuroprotection after neonatal encephalopathy in low-to-middle income countries: a systematic review and meta-analysis.

Erythropoietin monotherapy for neuroprotection after neonatal encephalopathy in low-to-middle income countries: a systematic review and meta-analysis.
复制标题

DOI:
10.1038/s41372-021-01132-4
复制
发表时间:
2021-09
期刊:
Journal of perinatology : official journal of the California Perinatal Association
影响因子:
--
通讯作者:
Thayyil S
Thayyil S
中科院分区:
其他
文献类型:
--
作者:
Ivain P;Montaldo P;Khan A;Elagovan R;Burgod C;Morales MM;Pant S;Thayyil S

文献摘要

参考文献

被引文献

相似文献

我们研究了促红细胞生成素单一疗法是否改善了中低收入国家(LMICs)新生儿脑病(NE)的近期和足月儿的神经发育结果。我们检索了Pubmed、Embase和Web of Science数据库,以确定使用促红细胞生成素(1500-12,500单位/公斤/剂量)或其衍生物治疗NE的研究。检索了5项研究,总共有348名婴儿在LMICs中。然而,在五项研究中,只有三项符合18个月或以上婴儿死亡或神经残疾的主要结果。促红细胞生成素降低了18个月或以后死亡(新生儿期和随访期)或神经功能障碍的风险(p < 0.05)。促红细胞生成素组的死亡或神经功能障碍发生率为27.6%,对照组为49.7%(风险比0.56(95%CI:0.42-0.75))。综合数据表明,促红细胞生成素单一治疗可改善低温治疗无效的LMICs患者去甲肾上腺素治疗后的预后。
We examined whether erythropoietin monotherapy improves neurodevelopmental outcomes in near-term and term infants with neonatal encephalopathy (NE) in low-middle income countries (LMICs). We searched Pubmed, Embase, and Web of Science databases to identify studies that used erythropoietin (1500–12,500 units/kg/dose) or a derivative to treat NE. Five studies, with a total of 348 infants in LMICs, were retrieved. However, only three of the five studies met the primary outcome of death or neuro-disability at 18 months of age or later. Erythropoietin reduced the risk of death (during the neonatal period and at follow-up) or neuro-disability at 18 months or later (p < 0.05). Death or neuro-disability occurred in 27.6% of the erythropoietin group and 49.7% of the comparison group (risk ratio 0.56 (95% CI: 0.42–0.75)). The pooled data suggest that erythropoietin monotherapy may improve outcomes after NE in LMICs where therapeutic hypothermia is not available.
DOI: 10.1016/j.clp.2015.04.004
发表时间: 2015-09
影响因子: 2.1
作者:
Juul SE;Pet GC
通讯作者: Pet GC
达贝泊汀对因脑病而接受降温的新生儿进行给药:一项安全性和药代动力学试验。
DOI: 10.1038/pr.2015.101
发表时间: 2015-09
期刊: Pediatric research
影响因子: 3.6
作者:
Baserga MC;Beachy JC;Roberts JK;Ward RM;DiGeronimo RJ;Walsh WF;Ohls RK;Anderson J;Mayock DE;Juul SE;Christensen RD;Loertscher MC;Stockmann C;Sherwin CM;Spigarelli MG;Yoder BA
通讯作者: Yoder BA
DOI: 10.1073/pnas.95.8.4635
发表时间: 1998-04-14
影响因子: 11.1
作者:
Sakanaka, M;Wen, TC;Sasaki, R
通讯作者: Sasaki, R
DOI: 10.1136/bmjpo-2017-000245
发表时间: 2018
影响因子: 2.6
作者:
Oliveira V;Kumutha JR;E N;Somanna J;Benkappa N;Bandya P;Chandrasekeran M;Swamy R;Mondkar J;Dewang K;Manerkar S;Sundaram M;Chinathambi K;Bharadwaj S;Bhat V;Madhava V;Nair M;Lally PJ;Montaldo P;Atreja G;Mendoza J;Bassett P;Ramji S;Shankaran S;Thayyil S
通讯作者: Thayyil S
DOI: 10.3109/14767058.2013.855894
发表时间: 2014-09-01
影响因子: 1.8
作者:
El Shimi, M. Sami;Awad, Hisham A.;El Maraghy, Mohamed O.
通讯作者: El Maraghy, Mohamed O.